Robert E. Africa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert E. Africa has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Brian J. McKinnon
Department of Otolaryngology-Head and Neck Surgery, University of Texas Medical Branch, Galveston, TX, 77555, USA; Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Meritus Health, Hagerstown, MD, 21742, USA
15 shared publicationsViran J. Ranasinghe
University of Texas Medical Branch
8 shared publicationsShahrukh R. Ali
Department of Otolaryngology-Head and Neck Surgery, University of Texas Medical Branch, Galveston, TX, 77555, USA
6 shared publications- Brian J. McKinnon
Department of Otolaryngology—Head and Neck Surgery University of Texas Medical Branch Galveston Texas USA
5 shared publications Charles A. Hughes
Department of Otolaryngology—Head and Neck Surgery University of Texas Medical Branch Galveston Texas USA
5 shared publicationsOrly M. Coblens
Department of Otolaryngology-Head and Neck Surgery, University of Texas Medical Branch, Galveston, TX, 77555, USA
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Evaluating the Impact of Analgesic Guidelines on Opioid Prescribing for Facial Local Flap Reconstruction
Objective: To evaluate the trends in opioid and nonopioid prescribing for facial local flap reconstruction in relation to the publication of guidelines by the American Academy of Otolaryngology–Head and Neck Surgery in April 2021. Methods: De-identified patient data were extracted from the TriNetX database, including individuals who received either opioid or non-opioid analgesics within 1–5 days following facial local flap reconstruction between January 1, 2013, and December 31, 2024. Prescribing trends were analyzed using interrupted time series analysis in Statistical Analysis System (SAS) version 9.4, with statistical significance defined as p < 0.05 to compare patterns in relation to the implementation of new opioid prescribing guidelines. Results: There was an initial significant decrease in the percentage of patients prescribed opioid medication by 4.23% following the publication of the guidelines (SE = 1.85; t = -2.29; p = 0.03). Following the initial period after the guideline publication, the trend continued to decrease by 0.12% per 3-month period (SE = 0.05; t = -2.33; p = 0.02). For non-opioid medication, there were no significant immediate or long-term changes after the guideline publication. Conclusions: There was an associated decrease in opioid prescribing after facial local flap reconstruction, and this was sustained after the guideline publication. No significant changes were identified for non-opioid prescribing.
- 28 October 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Open AccessEvaluating the Impact of Analgesic Guidelines on Opioid Prescribing for Facial Local Flap Reconstruction
Objective: To evaluate the trends in opioid and nonopioid prescribing for facial local flap reconstruction in relation to the publication of guidelines by the American Academy of Otolaryngology–Head and Neck Surgery in April 2021. Methods: De-identified patient data were extracted from the TriNetX database, including individuals who received either opioid or non-opioid analgesics within 1–5 days following facial local flap reconstruction between January 1, 2013, and December 31, 2024. Prescribing trends were analyzed using interrupted time series analysis in Statistical Analysis System (SAS) version 9.4, with statistical significance defined as p < 0.05 to compare patterns in relation to the implementation of new opioid prescribing guidelines. Results: There was an initial significant decrease in the percentage of patients prescribed opioid medication by 4.23% following the publication of the guidelines (SE = 1.85; t = -2.29; p = 0.03). Following the initial period after the guideline publication, the trend continued to decrease by 0.12% per 3-month period (SE = 0.05; t = -2.33; p = 0.02). For non-opioid medication, there were no significant immediate or long-term changes after the guideline publication. Conclusions: There was an associated decrease in opioid prescribing after facial local flap reconstruction, and this was sustained after the guideline publication. No significant changes were identified for non-opioid prescribing.
- Open Access
- 18 September 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (6) , 104939
Impact of kidney and liver transplant immunosuppression regimens on sinonasal disease
- 18 September 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (6) , 104939
Open AccessImpact of kidney and liver transplant immunosuppression regimens on sinonasal disease
- Open Access
- 16 September 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Necrotizing Fasciitis of the Cervicothoracic Region Secondary to Sternoclavicular Septic Arthritis: A Case Report
Necrotizing fasciitis is a rare but potentially life-threatening infection requiring early recognition and immediate surgical management to prevent significant morbidity and mortality. We present a case of cervicothoracic necrotizing fasciitis arising from sternoclavicular (SC) septic arthritis requiring multidisciplinary management. A 47-year-old male with history of poorly controlled diabetes mellitus, congestive heart failure, obesity, and tobacco use presented with progressive shoulder, neck and chest pain, dysphagia, odynophagia, and hoarseness. Laboratory evaluation demonstrated marked leukocytosis and severe hyperglycemia. Computed tomography imaging demonstrated extensive subcutaneous emphysema extending from the SC joint into the anterior chest wall, mediatsinum and retropharyngeal space. He underwent emergent surgical exploration that confirmed necrotizing infection with involvement of the sternum, clavicular head, sternocleidomastoid muscle and medial pectoralis muscle. His hospital course required serial operative debridement, wound vacuum therapy, and eventual chest wall reconstruction with a pectoralis major muscle flap. Infection control was achieved through coordinated care involving otolaryngology, cardiothoracic surgery, infectious disease, and critical care teams. This case highlights the importance of maintaining a low suspicion threshold for necrotizing infections in high-risk patients presenting with neck pain, severe examination findings, and systemic symptoms. Early imaging, prompt surgery interventtion, and multidisciplinary management are essential for survival in cervicothoracic necrotizing fasciitis.
- 16 September 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Open AccessNecrotizing Fasciitis of the Cervicothoracic Region Secondary to Sternoclavicular Septic Arthritis: A Case Report
Necrotizing fasciitis is a rare but potentially life-threatening infection requiring early recognition and immediate surgical management to prevent significant morbidity and mortality. We present a case of cervicothoracic necrotizing fasciitis arising from sternoclavicular (SC) septic arthritis requiring multidisciplinary management. A 47-year-old male with history of poorly controlled diabetes mellitus, congestive heart failure, obesity, and tobacco use presented with progressive shoulder, neck and chest pain, dysphagia, odynophagia, and hoarseness. Laboratory evaluation demonstrated marked leukocytosis and severe hyperglycemia. Computed tomography imaging demonstrated extensive subcutaneous emphysema extending from the SC joint into the anterior chest wall, mediatsinum and retropharyngeal space. He underwent emergent surgical exploration that confirmed necrotizing infection with involvement of the sternum, clavicular head, sternocleidomastoid muscle and medial pectoralis muscle. His hospital course required serial operative debridement, wound vacuum therapy, and eventual chest wall reconstruction with a pectoralis major muscle flap. Infection control was achieved through coordinated care involving otolaryngology, cardiothoracic surgery, infectious disease, and critical care teams. This case highlights the importance of maintaining a low suspicion threshold for necrotizing infections in high-risk patients presenting with neck pain, severe examination findings, and systemic symptoms. Early imaging, prompt surgery interventtion, and multidisciplinary management are essential for survival in cervicothoracic necrotizing fasciitis.
- Open Access
- 20 July 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (4) , e70508
Efficacy of Aspirin Usage in Free Flap Reconstruction of the Head and Neck
Objective: To compare head and neck free flap outcomes and complications following aspirin administration. Methods: This is a multicenter, retrospective cohort study using data from the 107 healthcare organizations in the United States. Adult patients (≥ 18 years) with a history of head and neck cancer who received non‐bony or bony free flap reconstruction were included. They were grouped by receiving 81 mg of aspirin (ASA81), 325 mg of aspirin (ASA325), or no aspirin on the same day of surgery or postoperatively. Primary outcomes included free flap failure, blood vessel repair, and need for flap revision. Relative risks (RR) with 95% confidence intervals (95% CI) were evaluated. Subgroup analysis was conducted between ASA81 and ASA325. Results: No differences in primary outcomes were observed for same day administration of aspirin. Postoperatively, ASA81 reduced the risk of flap failure and needing a blood vessel repair procedure (RR: 0.65[0.49–0.86]; 0.52[0.42–0.65]). ASA325 was also associated with a decreased risk of flap failure, need for blood vessel repair, and the need for flap revision procedures (RR: 0.10[0.08–0.13]; 0.57[0.46–0.71]; 0.37[0.32–0.41]) for all flap types. For non‐bony reconstruction, all primary outcomes were lower in the ASA81 group (RR: 0.72[0.53–0.98]; 0.53[0.41–0.68]; 0.73[0.59–0.89]). ASA325 for non‐bony flaps was also associated with lower rates of all three primary outcomes (RR: 0.47[0.34–0.64]; 0.63[0.49–0.80]; 0.80[0.68–0.94]). Aspirin use in bony flaps was associated with similar outcomes. ASA81 compared to ASA325 for non‐bony reconstruction was associated with higher flap failure (RR: 1.69[1.16–2.46]). Conclusion: For non‐bony and bony free flap reconstruction, aspirin was associated with decreased risks of free flap failure, blood vessel repair, and flap revision.
- 20 July 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (4) , e70508
Open AccessEfficacy of Aspirin Usage in Free Flap Reconstruction of the Head and Neck
Objective: To compare head and neck free flap outcomes and complications following aspirin administration. Methods: This is a multicenter, retrospective cohort study using data from the 107 healthcare organizations in the United States. Adult patients (≥ 18 years) with a history of head and neck cancer who received non‐bony or bony free flap reconstruction were included. They were grouped by receiving 81 mg of aspirin (ASA81), 325 mg of aspirin (ASA325), or no aspirin on the same day of surgery or postoperatively. Primary outcomes included free flap failure, blood vessel repair, and need for flap revision. Relative risks (RR) with 95% confidence intervals (95% CI) were evaluated. Subgroup analysis was conducted between ASA81 and ASA325. Results: No differences in primary outcomes were observed for same day administration of aspirin. Postoperatively, ASA81 reduced the risk of flap failure and needing a blood vessel repair procedure (RR: 0.65[0.49–0.86]; 0.52[0.42–0.65]). ASA325 was also associated with a decreased risk of flap failure, need for blood vessel repair, and the need for flap revision procedures (RR: 0.10[0.08–0.13]; 0.57[0.46–0.71]; 0.37[0.32–0.41]) for all flap types. For non‐bony reconstruction, all primary outcomes were lower in the ASA81 group (RR: 0.72[0.53–0.98]; 0.53[0.41–0.68]; 0.73[0.59–0.89]). ASA325 for non‐bony flaps was also associated with lower rates of all three primary outcomes (RR: 0.47[0.34–0.64]; 0.63[0.49–0.80]; 0.80[0.68–0.94]). Aspirin use in bony flaps was associated with similar outcomes. ASA81 compared to ASA325 for non‐bony reconstruction was associated with higher flap failure (RR: 1.69[1.16–2.46]). Conclusion: For non‐bony and bony free flap reconstruction, aspirin was associated with decreased risks of free flap failure, blood vessel repair, and flap revision.
- Open Access
- 30 June 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (4) , 104879
An assessment of pharmacologic deep vein thrombosis prophylaxis on head and neck free flap outcomes
- 30 June 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (4) , 104879
Open AccessAn assessment of pharmacologic deep vein thrombosis prophylaxis on head and neck free flap outcomes
- Open Access
- 11 May 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (3)
A Comparison of Outcomes and Complications Between Closed Reduction and Open Reduction of Mandibular Condylar and Subcondylar Fractures
Objective: To compare postoperative outcomes and complications between closed reduction and open reduction and internal fixation (ORIF) of condylar and subcondylar fractures. Methods: This is a multicenter, retrospective database study utilizing data from 64 healthcare organizations in the United States from January 1, 2010 to July 31, 2025. The TriNetX database was used to identify adult patients ages 18 years or older with a history of condylar or subcondylar fractures. These patients were either treated with closed reduction or ORIF. The relative risks (RRs) with 95% confidence intervals (CIs) for outcomes and complications were assessed within 1 year postoperatively. Results: Infection at or around the surgical site was more common with ORIF (RR: 0.64 [0.47–0.88]), while jaw pain and malocclusion were more frequent after closed reduction (RR: 1.73 [1.29–2.33]; 1.61 [1.21–2.15]). Malunion/nonunion and wound disruption rates were similar between groups (RR: 0.95 [0.61–1.48]; 1.33 [0.69–2.59]), and there were no facial nerve injuries. Patients treated with closed reduction had higher 30‐ and 90‐day emergency department visit rates (RR: 1.90 [1.55–2.33]; 1.73 [1.44–2.09]). Conclusion: Closed reduction is associated with a higher rate of jaw pain, malocclusion, and visits to the emergency department when compared to ORIF, but associated with an increased risk of infection. There was no risk of facial nerve injury or osteomyelitis with either treatment options. Level of Evidence: 3.
- 11 May 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (3)
Open AccessA Comparison of Outcomes and Complications Between Closed Reduction and Open Reduction of Mandibular Condylar and Subcondylar Fractures
Objective: To compare postoperative outcomes and complications between closed reduction and open reduction and internal fixation (ORIF) of condylar and subcondylar fractures. Methods: This is a multicenter, retrospective database study utilizing data from 64 healthcare organizations in the United States from January 1, 2010 to July 31, 2025. The TriNetX database was used to identify adult patients ages 18 years or older with a history of condylar or subcondylar fractures. These patients were either treated with closed reduction or ORIF. The relative risks (RRs) with 95% confidence intervals (CIs) for outcomes and complications were assessed within 1 year postoperatively. Results: Infection at or around the surgical site was more common with ORIF (RR: 0.64 [0.47–0.88]), while jaw pain and malocclusion were more frequent after closed reduction (RR: 1.73 [1.29–2.33]; 1.61 [1.21–2.15]). Malunion/nonunion and wound disruption rates were similar between groups (RR: 0.95 [0.61–1.48]; 1.33 [0.69–2.59]), and there were no facial nerve injuries. Patients treated with closed reduction had higher 30‐ and 90‐day emergency department visit rates (RR: 1.90 [1.55–2.33]; 1.73 [1.44–2.09]). Conclusion: Closed reduction is associated with a higher rate of jaw pain, malocclusion, and visits to the emergency department when compared to ORIF, but associated with an increased risk of infection. There was no risk of facial nerve injury or osteomyelitis with either treatment options. Level of Evidence: 3.
- Open Access
- 3 April 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (3) , 104823
Trends in opioid prescribing for septorhinoplasty in relation to the publication of Opioid Analgesia guidelines
- 3 April 2026
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 47 (3) , 104823
Open AccessTrends in opioid prescribing for septorhinoplasty in relation to the publication of Opioid Analgesia guidelines
- Open Access
- 13 March 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (2)
Outcomes of Head and Neck Free Flap Reconstruction Among Patients With Alcohol Use Disorder
Objective: To compare head and neck free flap outcomes and complications among patients with a history of alcohol use disorder. Methods: This is a multicenter retrospective study from January 1, 2010 to July 31, 2025 using data from 73 healthcare organizations in the United States. Adult patients 18 years or older with head and neck cancer undergoing non‐bony or bony free flap reconstruction were divided based on presence or absence of a history of alcohol use disorder before surgery. Primary outcomes examined up to 30 days after surgery included flap failure, need for vascular repair, and flap revision. Results: Patients with a history of alcohol use disorder within 6 months of surgery who underwent bony reconstruction had an increased risk of needing flap revision surgery and pneumonia (RR: 1.293[1.018, 1.642]; 1.947[1.337, 2.836]). A history of alcohol use disorder within 1 year prior to non‐bony free flap surgery had a higher risk of flap revision. (RR: 1.218[1.008, 1.472]). Sepsis and pneumonia were noted to have increased risks in relation to alcohol use disorders (RR: 1.522[1.055, 2.196]; 2.011[1.568, 2.581]). The risk of flap failure was not associated with a history of alcohol use disorders (RR: 1.159[0.878, 1.531]). Conclusion: Alcohol use disorder within 6 months prior to surgery is associated with an increased risk of flap revision surgery for bony reconstruction cases. For both non‐bony and bony free flaps, the risks of sepsis and pneumonia also increase significantly with alcohol use disorder. Level of Evidence: Level 3.
- 13 March 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (2)
Open AccessOutcomes of Head and Neck Free Flap Reconstruction Among Patients With Alcohol Use Disorder
Objective: To compare head and neck free flap outcomes and complications among patients with a history of alcohol use disorder. Methods: This is a multicenter retrospective study from January 1, 2010 to July 31, 2025 using data from 73 healthcare organizations in the United States. Adult patients 18 years or older with head and neck cancer undergoing non‐bony or bony free flap reconstruction were divided based on presence or absence of a history of alcohol use disorder before surgery. Primary outcomes examined up to 30 days after surgery included flap failure, need for vascular repair, and flap revision. Results: Patients with a history of alcohol use disorder within 6 months of surgery who underwent bony reconstruction had an increased risk of needing flap revision surgery and pneumonia (RR: 1.293[1.018, 1.642]; 1.947[1.337, 2.836]). A history of alcohol use disorder within 1 year prior to non‐bony free flap surgery had a higher risk of flap revision. (RR: 1.218[1.008, 1.472]). Sepsis and pneumonia were noted to have increased risks in relation to alcohol use disorders (RR: 1.522[1.055, 2.196]; 2.011[1.568, 2.581]). The risk of flap failure was not associated with a history of alcohol use disorders (RR: 1.159[0.878, 1.531]). Conclusion: Alcohol use disorder within 6 months prior to surgery is associated with an increased risk of flap revision surgery for bony reconstruction cases. For both non‐bony and bony free flaps, the risks of sepsis and pneumonia also increase significantly with alcohol use disorder. Level of Evidence: Level 3.
- 18 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (8) , 3381-3390
Association of Adult Chronic Rhinosinusitis With Pediatric Tonsillectomy and Adenoidectomy
Objectives: To evaluate epidemiological associations between the development of adult chronic rhinosinusitis (CRS) and treatment with surgery or biologic therapy following pediatric adenotonsillectomy. Methods: This is a multicenter, retrospective cohort study utilizing data from 100 healthcare organizations in the United States. The TriNetX database identified adults older than 18 years with or without prior childhood tonsillectomy and/or adenoidectomy. Outcomes included CRS without nasal polyposis (CRSsNP), with nasal polyposis (CRSwNP), sinus surgery, and biologic therapy. Subgroup analysis of patients with childhood obstructive sleep apnea (OSA), recurrent/chronic tonsillitis, adenoiditis, or middle ear disease was performed. Results: There was no statistically significant difference in the rate of adult CRSsNP, CRSwNP, surgery, and treatment with biologics after pediatric adenotonsillectomy for childhood OSA (HR: 0.94 [0.87–1.02]; 1.07 [0.79–1.44]; 0.87 [0.59–1.28]; 0.85 [0.66–1.09]). Children who had an adenoidectomy alone had a higher rate of CRSsNP as adults (HR: 1.55 [1.30–1.85]). Surgery for tonsillitis and adenoiditis had a higher rate of CRSwNP and surgery (HR: 1.63 [1.21–2.32]; 1.97 [1.36–2.86]). Adenoidectomy for adenoiditis was associated with CRSsNP (HR: 1.94 [1.73–2.19]). Adults with pediatric middle ear disease who had a childhood adenoidectomy alone had an increased rate of CRSsNP (HR: 1.47 [1.30–1.65]). Conclusions: Tonsillectomy with adenoidectomy in the setting of specific childhood infectious diseases was associated with adult CRSwNP and the need for sinus surgery, whereas adenoidectomy was associated with CRSsNP. Level of Evidence: 3.
- 18 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (8) , 3381-3390
Association of Adult Chronic Rhinosinusitis With Pediatric Tonsillectomy and Adenoidectomy
Objectives: To evaluate epidemiological associations between the development of adult chronic rhinosinusitis (CRS) and treatment with surgery or biologic therapy following pediatric adenotonsillectomy. Methods: This is a multicenter, retrospective cohort study utilizing data from 100 healthcare organizations in the United States. The TriNetX database identified adults older than 18 years with or without prior childhood tonsillectomy and/or adenoidectomy. Outcomes included CRS without nasal polyposis (CRSsNP), with nasal polyposis (CRSwNP), sinus surgery, and biologic therapy. Subgroup analysis of patients with childhood obstructive sleep apnea (OSA), recurrent/chronic tonsillitis, adenoiditis, or middle ear disease was performed. Results: There was no statistically significant difference in the rate of adult CRSsNP, CRSwNP, surgery, and treatment with biologics after pediatric adenotonsillectomy for childhood OSA (HR: 0.94 [0.87–1.02]; 1.07 [0.79–1.44]; 0.87 [0.59–1.28]; 0.85 [0.66–1.09]). Children who had an adenoidectomy alone had a higher rate of CRSsNP as adults (HR: 1.55 [1.30–1.85]). Surgery for tonsillitis and adenoiditis had a higher rate of CRSwNP and surgery (HR: 1.63 [1.21–2.32]; 1.97 [1.36–2.86]). Adenoidectomy for adenoiditis was associated with CRSsNP (HR: 1.94 [1.73–2.19]). Adults with pediatric middle ear disease who had a childhood adenoidectomy alone had an increased rate of CRSsNP (HR: 1.47 [1.30–1.65]). Conclusions: Tonsillectomy with adenoidectomy in the setting of specific childhood infectious diseases was associated with adult CRSwNP and the need for sinus surgery, whereas adenoidectomy was associated with CRSsNP. Level of Evidence: 3.
- Open Access
Evaluation of Opioid Prescribing Guidelines on Opioid Prescription Trends for Parotidectomy
Objective: To evaluate the trends in opioid and non‐opioid prescribing for parotidectomy in relation to the publication of opioid prescribing guidelines by the American Academy of Otolaryngology–Head and Neck Surgery (AAO‐HNS) in April 2021. Study Design: Retrospective. Setting: Eighty healthcare organizations in the United States. Methods: The TriNetX database was used to obtain deidentified patient data from January 1, 2013, to December 31, 2023. Patients who received a prescription for either opioid or non‐opioid analgesics within 1 to 5 days after parotidectomy were included. Prescription trends were analyzed using interrupted time series analysis in Statistical Analysis System (SAS) 9.4, with significance defined as P < .05, to assess changes in relation to the implementation of the AAO‐HNS guidelines. Results: Opioid prescribing had an immediate significant decrease by 7.44% ( P < .0001). The trend was sustained and continued to significantly decrease by 0.20% every 3 months ( P = .001). Non‐opioid prescribing in the initial period following the guideline publication increased significantly by 3.73% ( P < .0001). The trend continued to significantly increase by 0.12% every 3 months ( P < .0001). Conclusion: An immediate reduction in opioid prescribing was identified for parotidectomy, and this change was sustained. Conversely, non‐opioid prescribing had an associated immediate increase initially following the guideline publication, and this was also sustained.
Open AccessEvaluation of Opioid Prescribing Guidelines on Opioid Prescription Trends for Parotidectomy
Objective: To evaluate the trends in opioid and non‐opioid prescribing for parotidectomy in relation to the publication of opioid prescribing guidelines by the American Academy of Otolaryngology–Head and Neck Surgery (AAO‐HNS) in April 2021. Study Design: Retrospective. Setting: Eighty healthcare organizations in the United States. Methods: The TriNetX database was used to obtain deidentified patient data from January 1, 2013, to December 31, 2023. Patients who received a prescription for either opioid or non‐opioid analgesics within 1 to 5 days after parotidectomy were included. Prescription trends were analyzed using interrupted time series analysis in Statistical Analysis System (SAS) 9.4, with significance defined as P < .05, to assess changes in relation to the implementation of the AAO‐HNS guidelines. Results: Opioid prescribing had an immediate significant decrease by 7.44% ( P < .0001). The trend was sustained and continued to significantly decrease by 0.20% every 3 months ( P = .001). Non‐opioid prescribing in the initial period following the guideline publication increased significantly by 3.73% ( P < .0001). The trend continued to significantly increase by 0.12% every 3 months ( P < .0001). Conclusion: An immediate reduction in opioid prescribing was identified for parotidectomy, and this change was sustained. Conversely, non‐opioid prescribing had an associated immediate increase initially following the guideline publication, and this was also sustained.